| Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials WSME Theelen, D Chen, V Verma, BP Hobbs, HMU Peulen, JGJV Aerts, ... The Lancet Respiratory Medicine 9 (5), 467-475, 2021 | 359 | 2021 |
| Radiotherapy combined with immunotherapy: the dawn of cancer treatment Z Zhang, X Liu, D Chen, J Yu Signal transduction and targeted therapy 7 (1), 258, 2022 | 200 | 2022 |
| Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial J Welsh, H Menon, D Chen, V Verma, C Tang, M Altan, K Hess, ... Journal for immunotherapy of cancer 8 (2), 2020 | 178 | 2020 |
| Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma HB Barsoumian, R Ramapriyan, AI Younes, MS Caetano, H Menon, ... Journal for immunotherapy of cancer 8 (2), 2020 | 130 | 2020 |
| Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy H Menon, D Chen, R Ramapriyan, V Verma, HB Barsoumian, ... Journal for immunotherapy of cancer 7, 1-9, 2019 | 107 | 2019 |
| Absolute lymphocyte count predicts abscopal responses and outcomes in patients receiving combined immunotherapy and radiation therapy: analysis of 3 phase 1/2 trials D Chen, V Verma, RR Patel, HB Barsoumian, MA Cortez, JW Welsh International Journal of Radiation Oncology* Biology* Physics 108 (1), 196-203, 2020 | 87 | 2020 |
| Interaction between lymphopenia, radiotherapy technique, dosimetry, and survival outcomes in lung cancer patients receiving combined immunotherapy and radiotherapy D Chen, RR Patel, V Verma, R Ramapriyan, HB Barsoumian, MA Cortez, ... Radiotherapy and Oncology 150, 114-120, 2020 | 78 | 2020 |
| Phase I trial of pembrolizumab and radiation therapy after induction chemotherapy for extensive-stage small cell lung cancer JW Welsh, JV Heymach, D Chen, V Verma, TR Cushman, KR Hess, ... Journal of Thoracic Oncology 15 (2), 266-273, 2020 | 71 | 2020 |
| Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of … D Chen, H Menon, V Verma, C Guo, R Ramapriyan, H Barsoumian, ... Journal for immunotherapy of cancer 8 (1), 2020 | 71 | 2020 |
| Phase 1/2 trial of pembrolizumab and concurrent chemoradiation therapy for limited-stage SCLC JW Welsh, JV Heymach, C Guo, H Menon, K Klein, TR Cushman, ... Journal of Thoracic Oncology 15 (12), 1919-1927, 2020 | 67 | 2020 |
| Role of mitochondria in cancer immune evasion and potential therapeutic approaches K Klein, K He, AI Younes, HB Barsoumian, D Chen, T Ozgen, S Mosaffa, ... Frontiers in immunology 11, 573326, 2020 | 66 | 2020 |
| SHP-2 and PD-L1 inhibition combined with radiotherapy enhances systemic antitumor effects in an anti–PD-1–resistant model of non–small cell lung cancer D Chen, HB Barsoumian, L Yang, AI Younes, V Verma, Y Hu, H Menon, ... Cancer immunology research 8 (7), 883-894, 2020 | 66 | 2020 |
| Results of a phase 1/2 trial of chemoradiotherapy with simultaneous integrated boost of radiotherapy dose in unresectable locally advanced esophageal cancer D Chen, H Menon, V Verma, SN Seyedin, JA Ajani, WL Hofstetter, ... JAMA oncology 5 (11), 1597-1604, 2019 | 65 | 2019 |
| Screening differential circular RNA expression profiles reveal that hsa_circ_0128298 is a biomarker in the diagnosis and prognosis of hepatocellular carcinoma D Chen, C Zhang, J Lin, X Song, H Wang Cancer management and research, 1275-1283, 2018 | 60 | 2018 |
| High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial RR Patel, K He, HB Barsoumian, JY Chang, C Tang, V Verma, ... Radiotherapy and Oncology 162, 60-67, 2021 | 54 | 2021 |
| Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity D Chen, HB Barsoumian, G Fischer, L Yang, V Verma, AI Younes, Y Hu, ... Journal for immunotherapy of cancer 8 (1), 2020 | 54 | 2020 |
| Use of multi-site radiation therapy for systemic disease control RR Patel, V Verma, HB Barsoumian, MS Ning, SG Chun, C Tang, ... International Journal of Radiation Oncology* Biology* Physics 109 (2), 352-364, 2021 | 42 | 2021 |
| Preoperative to postoperative change in neutrophil-to-lymphocyte ratio predict survival in colorectal cancer patients D Guo, A Han, W Jing, D Chen, F Jin, M Li, L Kong, J Yu Future oncology 14 (12), 1187-1196, 2018 | 42 | 2018 |
| Combined treatment of non‐small cell lung cancer using radiotherapy and immunotherapy: challenges and updates S Shang, J Liu, V Verma, M Wu, J Welsh, J Yu, D Chen Cancer Communications 41 (11), 1086-1099, 2021 | 40 | 2021 |
| Total lymphocyte count, neutrophil–lymphocyte ratio, and platelet–lymphocyte ratio as prognostic factors in advanced non–small cell lung cancer with chemoradiotherapy X Song, D Chen, M Yuan, H Wang, Z Wang Cancer management and research, 6677-6683, 2018 | 39 | 2018 |
